EXECUTION VERSIONTarget License Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 Jurisdiction[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
IL-1 TARGET LICENSE AGREEMENT by and between XOMA (US) LLC and NOVARTIS PHARMA AGTarget License Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • New York
Contract Type FiledNovember 6th, 2017 Company Industry JurisdictionThis IL-1 TARGET LICENSE AGREEMENT (the “Agreement”) is entered into as of the 24th day of August, 2017 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 (“XOMA”), and Novartis Pharma AG, company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, CH 4056 Basel, Switzerland (“Novartis”). XOMA and Novartis are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”